organomegaly. Cardiovascacular, respiratory and nervous system reveals normal. X-ray of chest, ECG, Echocardiography and cardiac enzymes were also normal. Haematological investigation shows that Hb conc. 12.5 gm/dl, Normal PCV, ESR 5mm in 1 st hour, TC of WBC 10500/mm 3 , DC of WBC: Neutrophil 60%, Lymphocytes 28%, Eosinophil 09% Monocyte 02%, Basophil-01%. Platelet count was 22,00,000/mm 3 . Comments on peripheral blood film (PBF): RBC shows anisochromia with anisocytosis, and platelets are grossly increased in distribution with hyper aggregation and massive thrombocytosis. Bone marrow study reveals-moderately hyper cellular marrow with normal M-E ratio. Erythropoeisis was active and normoblastic. Granulopoeisis was also active and maturing into segmented form. Masses of aggregated platelet with marked increase in megakaryocytes, which are typically larger and have greater segmentation. All other investigations including liver function test, urea, creatinine and lipid profile revel normal. Special investigation e.g. Philadelphia chromosome also reveals negative.
Discussion:
Essential thrombocytosis is an uncommon myeloprolipherative disorder of unknown cause in which marked proliferation of the megakaryocytes in the bone marrow leads to elevation of platelet count. 3 Median age is 50-60 years and there is a slight increase in women, the disorder is suspected when elevated platelet count is found, less frequently the first sign is thrombosis, which is the most common clinical problem. The risk of thrombosis rises with age. Patient is expected to have erythromyalgia, painful burning of the hands and feet, but mucosal bleeding occurs occasionally. In this presentation, laboratory finding are that of very high Platelet count (>22,00,000/cmm), Hb level, ESR, PCV are normal and Philadelphia chromosome is negative. Bone marrow examination reveals marked increased in megakaryocytes which is typically large & with hyper segmentation but in reactive thrombocytosis they are often in cluster. Polycythemia rubra vera could be excluded, if PCV above the normal and Philadelphia chromosome is positive.
Management:
Principle of treatment is to control the platelet count so as to reduce the risk of thrombosis which is the major clinical problem. Patient may be placed in risk groups according to age, size of platelet count and previous episodes of thrombosis or haemorrhage. In those with high risk, the aim to keep the platelet count below <6,00,000/mm 3 , plateletphoresis is very helpful in short term management, low dose Aspirin (80mg/day) is commonly used to reduce the thrombotic risk, Hydroxyurea (0.5 to 2 g/dl) has been shown more effective agent to reduce the platelet count rapidly.
Conclusion:
Essential thrombocytosis is an indolent disorder and allows to long-term survival. Average survival is longer than 15 years. 3 The major source of immobility thrombosis can be reduced by appropriate platelet control. Late in the course of the disease, the bone marrow may be fibrotic and massive splenomegaly may occur. Sometimes with splenic infarction, there is a 10-15% risk of progression to myelofibrosis after 15 years and a 1-5% risk of transformation to acute leukaemia over 20 years. 3 
